Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Lilly stock was up 4.8% at $969.14, putting it on pace for a record closing high, according to Dow Jones Market Data. The ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

Choose Boston Business Journal as a preferred news source to see more of our reporting on Google. The deal could mean over ...

() -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million,​ granting the pharma giant ...

MeiraGTx (MGTX) stock climbs as the company partners with Eli Lilly (LLY) to develop and sell gene therapies for eye diseases ...

Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Plug Power (PLUG) ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

In the preceding three months, 12 analysts have released ratings for Eli Lilly (NYSE: LLY ), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...